Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Commerce oversight of FDA agenda will be influenced by WLF president and new staffer Slobodin.

Executive Summary

HOUSE COMMERCE OVERSIGHT OF FDA AGENDA WILL BE SHAPED BY WLF President and Legal Studies Division General Counsel Alan Slobodin, who is set to become counsel to the House Commerce Committee on Jan. 24. Although an employee of the full committee, Slobodin is likely to play a role in the development of hearings in the Oversight Subcommittee.

You may also be interested in...



Pediatric Prozac Phase IV Commitments Will Test Exclusivity Incentive

Lilly's Phase IV commitments for additional research on pediatric use of Prozac will serve as a high-profile test of FDA's pediatric exclusivity incentive

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel